Skip to main content
SpringerLink
Log in

Bispecific Antibody Armed T Cells to Target Cancer Cells

  • Protocol
  • First Online:
The Surfaceome

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1722))

Abstract

The common strategy for making bispecific antibodies (BsAbs) involves combining the variable domains of the desired monoclonal antibodies (mAbs) into a single bispecific structure. Bispecific immunotherapeutics has generated many different formats of BsAbs including chemical heteroconjugation of two complete molecules or fragments of monoclonal antibodies, quadroma, F(ab)2, diabodies, tandem diabodies, and single-chain antibodies (scFv). This chapter describes the process of generating activated T cells and arming T cells with heteroconjugated BsAbs to target cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744

    Article  CAS  PubMed  Google Scholar 

  2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

    Article  CAS  PubMed  Google Scholar 

  3. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773

    Article  CAS  PubMed  Google Scholar 

  4. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457–2466

    CAS  PubMed  Google Scholar 

  5. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    Article  CAS  PubMed  Google Scholar 

  6. Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517–522

    Article  CAS  PubMed  Google Scholar 

  7. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Riedle S, Rosel M, Zoller M (1998) In vivo activation and expansion of T cells by a bispecific antibody abolishes metastasis formation of human melanoma cells in SCID mice. Int J Cancer 75:908–918

    Article  CAS  PubMed  Google Scholar 

  9. Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179–209

    Article  CAS  PubMed  Google Scholar 

  10. Donohue JH, Ramsey PS, Kerr LA, Segal DM, McKean DJ (1990) Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates. Cancer Res 50:6508–6514

    CAS  PubMed  Google Scholar 

  11. Hombach A, Tillmann T, Jensen M, Heuser C, Sircar R, Diehl V, Kruis W, Pohl C (1997) Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Clin Exp Immunol 108:352–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155:219–225

    CAS  PubMed  Google Scholar 

  13. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690–697

    Article  CAS  PubMed  Google Scholar 

  14. Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P (1992) Engineering a humanized bispecific F(ab9)2 fragment for improved binding to T cells. Int J Cancer 7:45–50

    CAS  Google Scholar 

  15. Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M et al (2010) Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 277:477–487

    Article  CAS  PubMed  Google Scholar 

  16. Kufer P, Lutterbuse R, Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22:238–244

    Article  CAS  PubMed  Google Scholar 

  17. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103:4005–4010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH (2008) Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49:158–163

    Article  CAS  PubMed  Google Scholar 

  19. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y et al (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281–2292

    Article  CAS  PubMed  Google Scholar 

  20. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG (2008) A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 57:155–163

    Article  CAS  PubMed  Google Scholar 

  21. Bonino LD, De Monte LB, Sapnoli GC, Vola R, Mariani M, Barone D et al (1995) Bispecific monoclonal antibody anti-CD3 x antitenascin: an immunotherapeutic agent for human glioma. Int J Cancer 61:509–515

    Article  CAS  Google Scholar 

  22. Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S (2013) Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 13(83):2013

    Google Scholar 

  23. Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG (2012) Anti-CD3×anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 59:1198–1205

    Article  PubMed  PubMed Central  Google Scholar 

  24. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM et al (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463–1469

    Article  CAS  PubMed  Google Scholar 

  25. Bolhuis RLH, Lamers CHJ, Goey SH, Eggermont AMM, Trimbos JBMZ, Stoter G et al (1992) Adoptive immunotherapy of ovarian carcinoma with BSMAb-targeted lymphocytes: a multicenter study. Int J Cancer 7:78–81

    CAS  Google Scholar 

  26. Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M (1996) Cure of disseminated xenografted human Hodgkin’s tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood 87:2930–2937

    CAS  PubMed  Google Scholar 

  27. Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R (2014) Multiple infusions of CD20-targeted T cells and low dose IL-2, after stem cell transplant for high risk non-Hodgkin’s lymphoma: a pilot study. Bone Marrow Transplant 49(73–9):2014

    Google Scholar 

  28. Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L et al (2013) CD20-targeted T cells after stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 19:925–933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Baeuerle PA, Kufer P, Lutterbuse R (2003) Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 5:413–419

    CAS  PubMed  Google Scholar 

  30. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098–2103

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA

    Archana Thakur & Lawrence G. Lum

  2. Department of Neurosurgery, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

    Sandeep Mittal

  3. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

    Sandeep Mittal

Authors
  1. Archana Thakur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence G. Lum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandeep Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandeep Mittal .

Editor information

Editors and Affiliations

  1. School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China

    Kenneth R. Boheler

  2. Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Rebekah L. Gundry

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Thakur, A., Lum, L.G., Mittal, S. (2018). Bispecific Antibody Armed T Cells to Target Cancer Cells. In: Boheler, K., Gundry, R. (eds) The Surfaceome. Methods in Molecular Biology, vol 1722. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7553-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7553-2_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7551-8

  • Online ISBN: 978-1-4939-7553-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation